MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells

References

• Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. 2012. Cervical cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23:i27–i32.
   Web of Science ®Google Scholar
• Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, et al. 2012. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 7:e39167.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. 2010. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 285:19076–19084.
   PubMed Web of Science ®Google Scholar
• Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. 2007. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 104:16170–16175.
   PubMed Web of Science ®Google Scholar
• Higgs G, Slack F. 2013. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma. 3:17.
   PubMedGoogle Scholar
• Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, et al. 2013. MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 73:6972–6986.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Mendell JT. 2007. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96:R40–R44.
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61:69–90.
   PubMed Web of Science ®Google Scholar
• Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature. 448:807–810.
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL, Perala M. 2014. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 8:93–104.
   PubMed Web of Science ®Google Scholar
• Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. 2005. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer. 103:569–575.
   PubMed Web of Science ®Google Scholar
• Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. 2009. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine- resistant pancreatic cancer cells. Cancer Res. 69:6704–6712.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. 2011. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 224:484–495.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, et al. 2013. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 31:2086–2093.
   PubMed Web of Science ®Google Scholar
• Martin SG, St Johnston D. 2003. A role for drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature. 421:379–384.
   PubMed Web of Science ®Google Scholar
• Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z, et al. 2011. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71:1956–1967.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, et al. 2009. Onco-mir-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 1:288–295.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin. 63:11–30.
   PubMed Web of Science ®Google Scholar
• Tamura M, Uyama M, Sugiyama Y, Sato M. 2013. Canonical Wnt signaling activates miR-34 expression during osteoblastic differentiation. Mol Med Rep. 8:1807–1811.
   PubMed Web of Science ®Google Scholar
• Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. 2008. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e2557.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Inoue J, Kawano T, Kozaki K, Omura K, Inazawa J. 2014. The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res. 12:58–68.
   PubMed Web of Science ®Google Scholar